BR112017009850A2 - composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto - Google Patents

composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto

Info

Publication number
BR112017009850A2
BR112017009850A2 BR112017009850A BR112017009850A BR112017009850A2 BR 112017009850 A2 BR112017009850 A2 BR 112017009850A2 BR 112017009850 A BR112017009850 A BR 112017009850A BR 112017009850 A BR112017009850 A BR 112017009850A BR 112017009850 A2 BR112017009850 A2 BR 112017009850A2
Authority
BR
Brazil
Prior art keywords
compound
composition
hiv
compounds
enhancer amount
Prior art date
Application number
BR112017009850A
Other languages
English (en)
Inventor
Regueiro-Ren Alicia
Swidorski Jacob
A Meanwell Nicholas
Liu Zheng
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of BR112017009850A2 publication Critical patent/BR112017009850A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

compostos tendo propriedades fármaco e bioativas, suas composições farmacêuticas e métodos de uso são apresentados. em particular, os derivados do ácido betulínico que possuem atividade antiviral única são providos como inibidores da maturação do hiv, como representado pelos compostos das fórmulas i e ii. estes compostos são úteis para o tratamento de hiv e aids.
BR112017009850A 2014-11-14 2015-11-12 composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto BR112017009850A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462079977P 2014-11-14 2014-11-14
PCT/US2015/060344 WO2016077561A1 (en) 2014-11-14 2015-11-12 Oxolupene derivatives

Publications (1)

Publication Number Publication Date
BR112017009850A2 true BR112017009850A2 (pt) 2018-01-16

Family

ID=54697682

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009850A BR112017009850A2 (pt) 2014-11-14 2015-11-12 composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto

Country Status (10)

Country Link
US (1) US9969767B2 (pt)
EP (1) EP3218387A1 (pt)
JP (1) JP2017533937A (pt)
KR (1) KR20170087478A (pt)
CN (1) CN107250153A (pt)
AU (1) AU2015346303B2 (pt)
BR (1) BR112017009850A2 (pt)
CA (1) CA2967679A1 (pt)
RU (1) RU2017118489A (pt)
WO (1) WO2016077561A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016298669A1 (en) * 2015-07-28 2018-02-22 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating HIV infections
EP3328875A1 (en) * 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin derivatives for preventing or treating hiv infections
US20180273579A1 (en) * 2015-09-24 2018-09-27 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
WO2017125870A1 (en) * 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
CA2560266A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20090105203A1 (en) 2006-10-16 2009-04-23 Myriad Genetics, Incorporated Compounds for treating viral infections
TW200837074A (en) * 2006-11-03 2008-09-16 Panacos Pharmaceuticals Inc Extended triterpene derivatives
EP2250185A4 (en) * 2008-01-03 2011-11-16 Virochem Pharma Inc NEW LUPANDERIVATE
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US8431556B2 (en) * 2008-03-26 2013-04-30 Vertex Pharmaceuticals Incorporated C-21-keto lupane derivatives preparation and use thereof
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
WO2011100308A1 (en) * 2010-02-11 2011-08-18 Glaxosmithkline Llc Derivatives of betulin
PT2576586E (pt) * 2010-06-04 2015-10-23 Bristol Myers Squibb Co Amidas c-28 de derivados de ácido betulínico c-3 modificadas como inibidores de maturação de hiv
BR112012030818A2 (pt) * 2010-06-04 2019-09-24 Bristol-Myers Squibb Company "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
AU2012212509B2 (en) 2011-01-31 2016-01-21 ViiV Healthcare UK (No.4) Limited C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
EA023578B1 (ru) * 2011-01-31 2016-06-30 Бристол-Маерс Сквибб Компани C28-амины c3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
JO3387B1 (ar) * 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN103242413B (zh) * 2012-02-08 2015-08-26 江西青峰药业有限公司 Lupane三萜系衍生物及其药学用途
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity

Also Published As

Publication number Publication date
JP2017533937A (ja) 2017-11-16
US9969767B2 (en) 2018-05-15
EP3218387A1 (en) 2017-09-20
RU2017118489A (ru) 2018-12-14
US20170334946A1 (en) 2017-11-23
AU2015346303A1 (en) 2017-06-08
RU2017118489A3 (pt) 2019-02-13
CA2967679A1 (en) 2016-05-19
CN107250153A (zh) 2017-10-13
WO2016077561A1 (en) 2016-05-19
AU2015346303B2 (en) 2018-03-15
KR20170087478A (ko) 2017-07-28

Similar Documents

Publication Publication Date Title
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CL2017002650A1 (es) Compuestos novedosos
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
DOP2017000304A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2016000253A (es) Nuevos compuestos
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CL2018002084A1 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2603 DE 24-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.